Results 201 to 210 of about 365,010 (246)

Trends in Dermatopolymyositis Mortality, 1999–2022: A Nationwide Population‐Based Study, United States

Arthritis Care &Research, EarlyView.
We report the national burden of dermatopolymyositis mortality over the past quarter century using the US national vital statistics data. Age‐standardized mortality rates for dermatopolymyositis decreased at an annual rate of 3.8% each year, which was higher than the annual percent decrease for deaths from all other causes.
Elizabeth Matz, Ram R. Singh
wiley   +1 more source

Genetic analysis of Han-Chinese patients with isolated congenital ptosis. [PDF]

Int J Ophthalmol
Zhang QL, Yuan LM, Deng XY, Zheng W, Yi JH, Xu HB, Deng H.   +6 more
europepmc   +1 more source

​Did a Non‐Medical Biosimilar Switching Policy Cause an Increase in Non‐Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis?

Arthritis Care &Research, EarlyView.
Objective This study aimed to evaluate the impact of a series of policies that mandated switching patients with inflammatory arthritis (IA) from an originator biologic to a biosimilar in British Columbia, Canada, on health care resource use and cost.
HaoHung Dang, Sandra Blitz, Nick Bansback, Michael Law, Mark Harrison   +4 more
wiley   +1 more source

FAVOR 2.0: A reengineered functional annotation of variants online resource for interpreting genomic variation. [PDF]

Nucleic Acids Res
Zhou H, Verma V, Li X, Li Z, Shedd N, Li TC, Yang H, Zhang A, Borsari B, Buyske S, Gerstein M, Matise T, Zody MC, Neale B, Weng Z, Sunyaev SR, Lin X.   +16 more
europepmc   +1 more source

A Scoping Review on Artificial Intelligence–Supported Interventions for Nonpharmacologic Management of Chronic Rheumatic Diseases

Arthritis Care &Research, EarlyView.
This review summarizes artificial intelligence (AI)‐supported nonpharmacological interventions for adults with chronic rheumatic diseases, detailing their components, purpose, and current evidence base. We searched Embase, PubMed, Cochrane, and Scopus databases for studies describing AI‐supported interventions for adults with chronic rheumatic diseases.
Nirali Shah, Alexis Castellanos, Yen Chen, John Piette, Amy Bucher, Susan Murphy   +5 more
wiley   +1 more source

VIRE: a metagenome-derived, planetary-scale virome resource with environmental context. [PDF]

Nucleic Acids Res
Nishijima S, Fullam A, Schmidt TSB, Kuhn M, Bork P.   +4 more
europepmc   +1 more source

Hydroxychloroquine Associated With Lower Glomerular Filtration Rate Decline in Lupus Nephritis

Arthritis Care &Research, EarlyView.
Objective Hydroxychloroquine (HCQ) protects kidney function in lupus nephritis (LN) by preventing flares, yet some cohort studies show no significant benefit in kidney function with HCQ. Clarifying these conflicting findings by showing early and long‐term benefits of HCQ on kidney function preservation is critical.
Shivani Garg, Brad Rovin, Brad C. Astor, Tripti Singh, Fauzia Hollnagel, Megan Kuik, Lexie Kolton, Callie Saric, S. Sam Lim, Christie M. Bartels   +9 more
wiley   +1 more source

A comparative review of short genetic variant databases across humans and animal species. [PDF]

Brief Bioinform
Van Buren SL, Brown CT, Szmatoła T, Finno CJ.   +3 more
europepmc   +1 more source

Global and Regional Temporal Changes in Cross‐Country Inequalities of Site‐Specific Osteoarthritis Burden, 1990 to 2021

Arthritis Care &Research, EarlyView.
Objective This study examined the global and regional temporal changes in cross‐country inequalities of site‐specific osteoarthritis (OA) burden from 1990 to 2021. Methods Age‐standardized years lived with disability rates (ASYRs) for site‐specific OA across 204 countries and territories were obtained from the Global Burden of Diseases, Injuries, and ...
Haowei Chen, Lei Si, David J. Hunter, Lei Zhang, Zhe‐Sheng Chen, Xiaomeng Wang, Vicky Duong, Zhounan Zhou, Peihua Cao, Han Cen, Su'an Tang, Tianyu Chen, Houjun Xue, Zhaohua Zhu, Changhai Ding   +14 more
wiley   +1 more source

Identifying compounds to treat opiate use disorder by leveraging multi-omic data integration and multiple drug repurposing databases. [PDF]

Transl Psychiatry
Stratford JK, Carnes MU, Willis C, Minto MS, Elnimeiry L, Mathur R, Schu M, Quach BC, Carter J, Nolen T, Vandergrift N, Kosten TR, Johnson EO, Webb BT.   +13 more
europepmc   +1 more source